Overview
About Eirgen Pharma
At Eirgen Pharma, we are a research-driven Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) specializing in the development, manufacture, and supply of a broad range of high potency Oral Solid Dose (OSD) products for the human and veterinary pharmaceutical markets.
Our expertise lies in supporting the full product lifecycle — from early-stage formulation development and clinical trial supply to large-scale commercial manufacturing and packaging. We work closely with specialty pharma companies and global innovators to deliver tailored, high-quality solutions that meet complex development and manufacturing needs.
With specialized capabilities in high containment and high potency manufacturing, Eirgen is recognized for our ability to manage challenging molecules safely and efficiently, ensuring consistent quality and regulatory compliance across global markets.
In 2025, we are expanding our operations with the launch of a new, state-of-the-art manufacturing facility, increasing our capacity to over 500 million units annually. This major investment strengthens our position as a partner of choice for companies seeking agile, scalable, and expert support for their high potency and specialty OSD products.
At Eirgen, we combine scientific excellence with operational flexibility to help our partners bring important medicines to patients around the world.
Our expertise lies in supporting the full product lifecycle — from early-stage formulation development and clinical trial supply to large-scale commercial manufacturing and packaging. We work closely with specialty pharma companies and global innovators to deliver tailored, high-quality solutions that meet complex development and manufacturing needs.
With specialized capabilities in high containment and high potency manufacturing, Eirgen is recognized for our ability to manage challenging molecules safely and efficiently, ensuring consistent quality and regulatory compliance across global markets.
In 2025, we are expanding our operations with the launch of a new, state-of-the-art manufacturing facility, increasing our capacity to over 500 million units annually. This major investment strengthens our position as a partner of choice for companies seeking agile, scalable, and expert support for their high potency and specialty OSD products.
At Eirgen, we combine scientific excellence with operational flexibility to help our partners bring important medicines to patients around the world.